New Phase 3 clinical data and real-world findings for Teva Pharmaceutical Industries’ long-acting injectable antipsychotics—olanzapine LAI and Uzedy—were presented between September 15 and 19, 2026, at the Psych Congress 2026 conference in New Orleans, according to announcements from partner Medincell. Both therapies utilize Medincell’s proprietary BEPO technology platform, licensed to Teva under the name SteadyTeq.
Phase 3 SOLARIS Trial Results for Olanzapine LAI
According to post hoc analyses from the Phase 3 SOLARIS study presented by Teva, monthly subcutaneous administration of olanzapine LAI demonstrated sustained efficacy in adults with schizophrenia. During the long-term treatment period, 56% of trial participants achieved clinical stabilization. Among those stabilized patients, 4% experienced a subsequent relapse, while 21% of patients treated for at least six months met the study’s criteria for remission, as reported by Medincell. Additional analyses outlined potential transition pathways for patients moving from oral olanzapine or short-acting injectable formulations to the monthly long-acting version. Olanzapine LAI remains an investigational treatment that has not yet received approval from any regulatory authority, with a decision from the U.S. Food and Drug Administration expected during the fourth quarter of 2026.
Real-World Outcomes and Health Resource Utilization for Uzedy
Real-world data presented at the conference highlighted treatment continuity and healthcare utilization patterns for Uzedy, an extended-release injectable risperidone suspension. According to Medincell, real-world findings showed improved treatment persistence among adults with schizophrenia treated with Uzedy compared to several alternative long-acting injectable antipsychotics. Furthermore, data demonstrated a reduction in health resource utilization compared to monthly paliperidone palmitate. Separate analyses evaluated outcomes for adults with bipolar I disorder who transitioned from oral antipsychotic regimens to Uzedy therapy.
Technology Platform and Regulatory Timeline
Both treatments leverage Medincell’s BEPO polymer-based drug delivery technology, which controls the release profile of active pharmaceutical ingredients via subcutaneous injection. Teva manages commercialization and regulatory filings under its SteadyTeq framework. While Uzedy is currently on the market, the regulatory review for once-monthly subcutaneous olanzapine LAI proceeds toward its anticipated fourth-quarter 2026 target date with the FDA.
Related reading